Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

10.54 +0.40 (+3.94%)
Streaming Delayed Price Updated: 1:49 PM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Certara, Inc. - Common Stock

< Previous 1 2 3 Next >
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
From Certara
Via GlobeNewswire
Certara Announces Expansion of Clinical Technology Collaboration with Merck
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality 
From Certara
Via GlobeNewswire
Certara Reports First Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies 
From Certara
Via GlobeNewswire
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization
From Certara
Via GlobeNewswire
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making 
From Certara
Via GlobeNewswire
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
McKemey joins Certara to accelerate growth of its strategic drug development solutions 
From Certara
Via GlobeNewswire
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Certara
Via GlobeNewswire
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Certara
Via GlobeNewswire
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list 
From Certara
Via GlobeNewswire
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Appoints John Reynders as New Independent Board Member
From Certara
Via GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
From Certara
Via GlobeNewswire
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through... 
From Certara
Via GlobeNewswire
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and... 
From Certara
Via GlobeNewswire
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Launches Phoenix™ Version 8.5 Drug Development Software
From Certara
Via GlobeNewswire
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
From Certara
Via GlobeNewswire
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
Via MarketBeat
Topics Artificial Intelligence
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
From Certara
Via GlobeNewswire
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies 
From Certara
Via GlobeNewswire
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Appoints New Chief Human Resources Officer & General Counsel
From Certara
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.